Two opposing gene expression patterns within ATRX aberrant neuroblastoma.
Autorzy:
van Gerven MR; Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands. Schild L; Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands. van Arkel J; Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands. Koopmans B; Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands. Broeils LA; Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands. Meijs LAM; Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands. van Oosterhout R; Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands. van Noesel MM; Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands.; Department of Cancer and Imaging, University Medical Center Utrecht, Utrecht, Utrecht, The Netherlands. Koster J; Department of Oncogenomics, University Medical Center Amsterdam, Amsterdam, North-Holland, The Netherlands. van Hooff SR; Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands. MolenaarJJ; Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands.; Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Utrecht, The Netherlands. van den Boogaard ML; Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Aug 04; Vol. 18 (8), pp. e0289084. Date of Electronic Publication: 2023 Aug 04 (Print Publication: 2023).
Systematic discovery of gene fusions in pediatric cancer by integrating RNA-seq and WGS.
Autorzy:
van Belzen IAEM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Cai C; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. van Tuil M; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Badloe S; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Strengman E; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Janse A; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Verwiel ETP; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. van der Leest DFM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Kester L; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. MolenaarJJ; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. Meijerink J; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Drost J; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Oncode Institute, Utrecht, The Netherlands. Peng WC; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Kerstens HHD; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Tops BBJ; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Holstege FCP; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Kemmeren P; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. .; Center for Molecular Medicine, UMC Utrecht and Utrecht University, Utrecht, The Netherlands. . Hehir-Kwa JY; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Jul 03; Vol. 23 (1), pp. 618. Date of Electronic Publication: 2023 Jul 03.
The potential of PARP as a therapeutic target across pediatric solid malignancies.
Autorzy:
Keller KM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Koetsier J; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Schild L; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Amo-Addae V; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Eising S; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. van den Handel K; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Ober K; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Koopmans B; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Essing A; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. van den Boogaard ML; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Langenberg KPS; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Jäger N; Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.; Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany. Kool M; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.; Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany. Pfister S; Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.; Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany. Dolman MEM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Children's Cancer Institute, Lowy Cancer Centre, UNSW Sydney, Kensington, NSW, Australia.; School of Women's and Children's Health, Faculty of Medicine, UNSW Sydney, Sydney, NSW, Australia. MolenaarJJ; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. j.j.molenaar@prinsesmaximacentrum.nl.; Department of Pharmaceutical Sciences, University Utrecht, Utrecht, the Netherlands. j.j.molenaar@prinsesmaximacentrum.nl. van Hooff SR; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Apr 05; Vol. 23 (1), pp. 310. Date of Electronic Publication: 2023 Apr 05.
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.
Autorzy:
Berlak M; Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.; Berlin School of Integrative Oncology (BSIO), Augustenburger Platz 1, 13353, Berlin, Germany.; Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, Kelchstr.31, 12169, Berlin, Germany. Tucker E; Paediatric Solid Tumour Biology and Therapeutics Team, Clinical Division and Cancer Therapeutics Division, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK. Dorel M; Otto Warburg Laboratory Gene Regulation and Systems Biology of Cancer, Max Planck Institute for Molecular Genetics, Berlin, Germany.; Institute of Pathology, Charité-Universitätsmedizin Berlin, 10117, Berlin, Germany.; IRI Life Sciences, Humboldt University Berlin, 10115, Berlin, Germany. Winkler A; Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. McGearey A; Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. Rodriguez-Fos E; Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.; Experimental and Clinical Research Center (ECRC) of the Charité and Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, 13125, Berlin, Germany. da Costa BM; Paediatric Solid Tumour Biology and Therapeutics Team, Clinical Division and Cancer Therapeutics Division, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK. Barker K; Paediatric Solid Tumour Biology and Therapeutics Team, Clinical Division and Cancer Therapeutics Division, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK. Fyle E; Paediatric Solid Tumour Biology and Therapeutics Team, Clinical Division and Cancer Therapeutics Division, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK. Calton E; Paediatric Solid Tumour Biology and Therapeutics Team, Clinical Division and Cancer Therapeutics Division, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK. Eising S; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands. Ober K; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands. Hughes D; Molecular Diagnostics Department, The Institute of Cancer Research and Clinical Genomics, The Royal Marsden NHS Foundation, London, UK. Koutroumanidou E; Molecular Diagnostics Department, The Institute of Cancer Research and Clinical Genomics, The Royal Marsden NHS Foundation, London, UK. Carter P; Molecular Diagnostics Department, The Institute of Cancer Research and Clinical Genomics, The Royal Marsden NHS Foundation, London, UK. Stankunaite R; Molecular Diagnostics Department, The Institute of Cancer Research and Clinical Genomics, The Royal Marsden NHS Foundation, London, UK. Proszek P; Molecular Diagnostics Department, The Institute of Cancer Research and Clinical Genomics, The Royal Marsden NHS Foundation, London, UK. Jain N; Cancer Section, UCL Great Ormond Street Institute of Child Health, London, UK. Rosswog C; Department of Experimental Pediatric Oncology, Center for Molecular Medicine Cologne, 50931, Cologne, Germany. Dorado-Garcia H; Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. MolenaarJJ; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of pharmaceutical sciences, Utrecht University, Utrecht, The Netherlands. Hubank M; Molecular Diagnostics Department, The Institute of Cancer Research and Clinical Genomics, The Royal Marsden NHS Foundation, London, UK. Barone G; Cancer Section, UCL Great Ormond Street Institute of Child Health, London, UK. Anderson J; Cancer Section, UCL Great Ormond Street Institute of Child Health, London, UK. Lang P; Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.; Department of Pediatric Hematology and Oncology, University Hospital, Tübingen, Germany. Deubzer HE; Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.; Experimental and Clinical Research Center (ECRC) of the Charité and Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, 13125, Berlin, Germany.; German Cancer Consortium (DKTK), Berlin, Germany.; German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany. Künkele A; Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.; German Cancer Consortium (DKTK), Berlin, Germany.; German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.; Berlin Institute of Health (BIH) at Charité-Universitätsmedizin Berlin, 10117, Berlin, Germany. Fischer M; Department of Experimental Pediatric Oncology, Center for Molecular Medicine Cologne, 50931, Cologne, Germany. Eggert A; Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.; German Cancer Consortium (DKTK), Berlin, Germany.; German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.; Berlin Institute of Health (BIH) at Charité-Universitätsmedizin Berlin, 10117, Berlin, Germany. Kloft C; Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, Kelchstr.31, 12169, Berlin, Germany. Henssen AG; Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.; Experimental and Clinical Research Center (ECRC) of the Charité and Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, 13125, Berlin, Germany.; German Cancer Consortium (DKTK), Berlin, Germany.; German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.; Berlin Institute of Health (BIH) at Charité-Universitätsmedizin Berlin, 10117, Berlin, Germany. Boettcher M; Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), 06120, Halle, Germany. Hertwig F; Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. Blüthgen N; Institute of Pathology, Charité-Universitätsmedizin Berlin, 10117, Berlin, Germany.; IRI Life Sciences, Humboldt University Berlin, 10115, Berlin, Germany.; German Cancer Consortium (DKTK), Berlin, Germany.; German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.; Berlin Institute of Health (BIH) at Charité-Universitätsmedizin Berlin, 10117, Berlin, Germany. Chesler L; Paediatric Solid Tumour Biology and Therapeutics Team, Clinical Division and Cancer Therapeutics Division, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK. Schulte JH; Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. .; German Cancer Consortium (DKTK), Berlin, Germany. .; German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany. .
Pokaż więcej
Źródło:
Molecular cancer [Mol Cancer] 2022 Jun 10; Vol. 21 (1), pp. 126. Date of Electronic Publication: 2022 Jun 10.
The Landscape of Pediatric Precision Oncology: Program Design, Actionable Alterations, and Clinical Trial Development.
Autorzy:
Langenberg KPS; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands. Looze EJ; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands. MolenaarJJ; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands.; Department of Pharmaceutical Sciences, Utrecht University, P.O. Box 80082, 3508 TB Utrecht, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2021 Aug 27; Vol. 13 (17). Date of Electronic Publication: 2021 Aug 27.
Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma.
Autorzy:
Wellens LM; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Oncode Institute, Hubrecht Institute - KNAW, Utrecht, The Netherlands.; Cancer Genomics Center, Utrecht, The Netherlands. Deken MM; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands. Sier CFM; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands. Johnson HR; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Oncode Institute, Hubrecht Institute - KNAW, Utrecht, The Netherlands.; Cancer Genomics Center, Utrecht, The Netherlands. de la Jara Ortiz F; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands. Bhairosingh SS; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands. Houvast RD; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands. Kholosy WM; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands. Baart VM; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands. Pieters AMMJ; Department of Surgery, Maasstad Hospital, Rotterdam, The Netherlands. de Krijger RR; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands. MolenaarJJ; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands. Wehrens EJ; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Oncode Institute, Hubrecht Institute - KNAW, Utrecht, The Netherlands.; Cancer Genomics Center, Utrecht, The Netherlands. Dekkers JF; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Oncode Institute, Hubrecht Institute - KNAW, Utrecht, The Netherlands.; Cancer Genomics Center, Utrecht, The Netherlands. Wijnen MHWA; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands. Vahrmeijer AL; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands. Rios AC; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands. .; Oncode Institute, Hubrecht Institute - KNAW, Utrecht, The Netherlands. .; Cancer Genomics Center, Utrecht, The Netherlands. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2020 Oct 19; Vol. 10 (1), pp. 17667. Date of Electronic Publication: 2020 Oct 19.
DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells.
Autorzy:
Dolman ME; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. van der Ploeg I; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. Koster J; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. Bate-Eya LT; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. Versteeg R; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. Caron HN; Department of Pediatric Oncology, Emma Kinderziekenhuis, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. MolenaarJJ; Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2015 Dec 30; Vol. 10 (12), pp. e0145744. Date of Electronic Publication: 2015 Dec 30 (Print Publication: 2015).
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.
Autorzy:
Eleveld TF; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands. Oldridge DA; 1] Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [2] Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [3] Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Bernard V; ICGEX Platform, Institut Curie, Paris, France. Koster J; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands. Colmet Daage L; 1] ICGEX Platform, Institut Curie, Paris, France. [2] Laboratory RTOP (Recherche Translationelle en Oncologie Pédiatrique), Transfer Department, Institut Curie, Paris, France. Diskin SJ; 1] Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [2] Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [3] Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Schild L; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands. Bentahar NB; ICGEX Platform, Institut Curie, Paris, France. Bellini A; Laboratory RTOP (Recherche Translationelle en Oncologie Pédiatrique), Transfer Department, Institut Curie, Paris, France. Chicard M; Laboratory RTOP (Recherche Translationelle en Oncologie Pédiatrique), Transfer Department, Institut Curie, Paris, France. Lapouble E; Unité de Génétique Somatique, Institut Curie, Paris, France. Combaret V; Centre Léon-Bérard, Laboratoire de Recherche Translationnelle Lyon, Lyon, France. Legoix-Né P; ICGEX Platform, Institut Curie, Paris, France. Michon J; Département de Pédiatrie, Institut Curie, Paris, France. Pugh TJ; Princess Margaret Cancer Centre, University Health Network; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. Hart LS; 1] Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [2] Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Rader J; 1] Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [2] Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Attiyeh EF; 1] Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [2] Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [3] Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Wei JS; Pediatric Oncology Branch, Oncogenomics Section, Center for Cancer Research, US National Institutes of Health, Gaithersburg, Maryland, USA. Zhang S; Pediatric Oncology Branch, Oncogenomics Section, Center for Cancer Research, US National Institutes of Health, Gaithersburg, Maryland, USA. Naranjo A; Department of Biostatistics, University of Florida, Children's Oncology Group (COG), Gainesville, Florida, USA. Gastier-Foster JM; 1] The Ohio State University College of Medicine, Columbus, Ohio, USA. [2] Biopathology Center, Nationwide Children's Hospital, Columbus, Ohio, USA. Hogarty MD; 1] Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [2] Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [3] Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Asgharzadeh S; 1] Division of Hematology/Oncology, Children's Hospital Los Angeles, Los Angeles, California, USA. [2] Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California, USA. [3] Keck School of Medicine, University of Southern California, Los Angeles, California, USA. Smith MA; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA. Guidry Auvil JM; Office of Cancer Genomics, National Cancer Institute, Bethesda, Maryland, USA. Watkins TB; Translational Cancer Therapeutics Laboratory, Cancer Research UK, London, UK. Zwijnenburg DA; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands. Ebus ME; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands. van Sluis P; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands. Hakkert A; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands. van Wezel E; 1] Department of Experimental Immunohematology, Sanquin Research, Amsterdam, the Netherlands. [2] Landsteiner Laboratory, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands. van der Schoot CE; 1] Department of Experimental Immunohematology, Sanquin Research, Amsterdam, the Netherlands. [2] Landsteiner Laboratory, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands. Westerhout EM; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands. Schulte JH; 1] Department of Pediatric Oncology and Hematology, Charité University Medicine, Berlin, Germany. [2] German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany. [3] Department of Pediatric Oncology and Hematology, University Children's Hospital Essen, Essen, Germany. [4] Translational Neuro-Oncology, West German Cancer Center (WTZ), University Hospital Essen, Essen, Germany. Tytgat GA; Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands. Dolman ME; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands. Janoueix-Lerosey I; INSERM U830, Laboratoire de Génétique et Biologie des Cancers, Institut Curie, Paris, France. Gerhard DS; Biopathology Center, Nationwide Children's Hospital, Columbus, Ohio, USA. Caron HN; Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands. Delattre O; INSERM U830, Laboratoire de Génétique et Biologie des Cancers, Institut Curie, Paris, France. Khan J; Pediatric Oncology Branch, Oncogenomics Section, Center for Cancer Research, US National Institutes of Health, Gaithersburg, Maryland, USA. Versteeg R; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands. Schleiermacher G; 1] Laboratory RTOP (Recherche Translationelle en Oncologie Pédiatrique), Transfer Department, Institut Curie, Paris, France. [2] Département de Pédiatrie, Institut Curie, Paris, France. [3] INSERM U830, Laboratoire de Génétique et Biologie des Cancers, Institut Curie, Paris, France. MolenaarJJ; Department of Oncogenomics, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands. Maris JM; 1] Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [2] Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [3] Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Pokaż więcej
Źródło:
Nature genetics [Nat Genet] 2015 Aug; Vol. 47 (8), pp. 864-71. Date of Electronic Publication: 2015 Jun 29.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
